

Toshifumi Tada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2862685/publications.pdf>

Version: 2024-02-01

152
papers

7,037
citations

94269

37
h-index

69108

77
g-index

153
all docs

153
docs citations

153
times ranked

6224
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-558.	0.8	1,810
2	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	1.8	360
3	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	2.4	217
4	Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1031-1036.	1.4	198
5	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. <i>Liver Cancer</i> , 2017, 6, 204-215.	4.2	159
6	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. <i>Liver Cancer</i> , 2019, 8, 121-129.	4.2	159
7	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	2.9	150
8	Evolution of Hypointense Hepatocellular Nodules Observed Only in the Hepatobiliary Phase of Gadoxetate Disodium—Enhanced MRI. <i>American Journal of Roentgenology</i> , 2011, 197, 58-63.	1.0	141
9	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions—Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 3719-3728.	1.3	131
10	Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. <i>Liver Cancer</i> , 2015, 4, 126-136.	4.2	125
11	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. <i>Journal of Hepatology</i> , 2016, 65, 48-56.	1.8	125
12	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. <i>Journal of Hepatology</i> , 2013, 58, 427-433.	1.8	124
13	Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. <i>Digestive Diseases</i> , 2017, 35, 602-610.	0.8	113
14	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 137-146.	1.3	112
15	Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 2679-2687.	0.7	102
16	Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1982-1988.	1.4	91
17	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. <i>Hepatology Research</i> , 2019, 49, 111-117.	1.8	81
18	Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. <i>Journal of Gastroenterology</i> , 2016, 51, 741-747.	2.3	72

#	ARTICLE	IF	CITATIONS
19	Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. <i>American Journal of Roentgenology</i> , 2019, 212, 332-341.	1.0	70
20	Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. <i>Journal of Hepatology</i> , 2013, 58, 1174-1180.	1.8	66
21	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	2.9	66
22	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 277-285.	0.9	66
23	Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 848-853.	1.9	63
24	High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2014, 49, 555-563.	2.3	57
25	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. <i>Liver International</i> , 2016, 36, 817-826.	1.9	57
26	Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices. <i>Hepatology Research</i> , 2015, 45, E122-9.	1.8	53
27	Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976.	1.9	51
28	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1012-1022.	1.9	50
29	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017, 116, 441-447.	2.9	46
30	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	1.9	45
31	A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. <i>Surgery</i> , 2015, 157, 699-707.	1.0	44
32	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. <i>Hepatology Research</i> , 2020, 50, 75-83.	1.8	44
33	Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 546-551.	0.8	43
34	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2022, 5, e1464.	0.6	43
35	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. <i>Journal of Hepatology</i> , 2017, 66, 521-527.	1.8	41
36	Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2011-2018.	1.4	41

#	ARTICLE	IF	CITATIONS
37	The chances of hepatic resection curing hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 711-717.	1.8	41
38	Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. <i>Journal of Gastroenterology</i> , 2011, 46, 536-544.	2.3	40
39	Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. <i>Cancer Science</i> , 2017, 108, 1414-1420.	1.7	40
40	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1066-1073.	1.4	40
41	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 334-340.	0.9	39
42	Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 899-910.	2.0	38
43	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 73-83.	4.2	37
44	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. <i>Oncology</i> , 2016, 91, 153-161.	0.9	36
45	Differences in the impact of prognostic factors for hepatocellular carcinoma over time. <i>Cancer Science</i> , 2017, 108, 2438-2444.	1.7	35
46	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. <i>Hepatology Research</i> , 2020, 50, 190-198.	1.8	35
47	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. <i>Liver Cancer</i> , 2020, 9, 734-743.	4.2	35
48	Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices. <i>Hepatology Research</i> , 2019, 49, 676-686.	1.8	34
49	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 293.	1.7	34
50	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. <i>Hepatology Research</i> , 2022, 52, 773-783.	1.8	34
51	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	1.8	33
52	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	1.6	30
53	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 918-925.	1.4	29
54	Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging-determined proton density fat fraction. <i>Hepatology Research</i> , 2020, 50, 1319-1327.	1.8	29

#	ARTICLE	IF	CITATIONS
55	Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. <i>Liver Cancer</i> , 2020, 9, 41-49.	4.2	28
56	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1812-1819.	1.4	28
57	Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 810-822.	1.8	27
58	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 698-706.	0.8	27
59	Transarterial Chemoembolization for Hepatitis B Virus-associated Hepatocellular Carcinoma: Improved Survival after Concomitant Treatment with Nucleoside Analogues. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 317-322.e1.	0.2	26
60	Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. <i>Journal of Gastroenterology</i> , 2017, 52, 104-112.	2.3	26
61	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. <i>Liver International</i> , 2019, 39, 448-454.	1.9	26
62	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 1276-1284.	2.3	25
63	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	2.0	25
64	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria – Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	1.8	25
65	Does first-line treatment have prognostic impact for unresectable HCC? Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	1.3	25
66	Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1412-1419.	1.4	24
67	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 295-302.	0.9	24
68	Serum Levels of Î± ₂ -Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 162-170.e4.	2.4	24
69	Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 687-694.	1.4	23
70	Post-treatment levels of Î± ₂ -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. <i>Hepatology Research</i> , 2017, 47, 1021-1031.	1.8	22
71	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model. <i>Journal of Gastroenterology</i> , 2018, 53, 1196-1205.	2.3	22
72	Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. <i>Liver Cancer</i> , 2020, 9, 518-528.	4.2	22

#	ARTICLE	IF	CITATIONS
73	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. <i>Hepatology Research</i> , 2021, 51, 201-215.	1.8	22
74	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 436-441.	1.4	21
75	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	1.3	21
76	New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Biomarkers</i> , 2018, 23, 328-334.	0.9	20
77	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 664-670.	1.9	20
78	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 511-520.	0.6	20
79	Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. <i>Journal of Gastroenterology</i> , 2015, 50, 85-94.	2.3	19
80	Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. <i>European Radiology</i> , 2014, 24, 2157-2166.	2.3	18
81	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. <i>Journal of Gastroenterology</i> , 2016, 51, 380-389.	2.3	18
82	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz185.	0.4	18
83	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	2.3	18
84	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. <i>Targeted Oncology</i> , 2021, 16, 249-254.	1.7	18
85	Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00337.	1.3	18
86	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
87	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	1.8	18
88	Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 3070-3078.	0.7	16
89	Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 451-458.	1.4	16
90	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 851-866.	1.8	16

#	ARTICLE	IF	CITATIONS
91	Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1 and 2 infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. <i>Journal of Medical Virology</i> , 2021, 93, 6247-6256.	2.5	16
92	Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. <i>Liver Cancer</i> , 2022, 11, 527-539.	4.2	16
93	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
94	Utility of the $FIB-4$ Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. <i>Journal of Viral Hepatitis</i> , 2015, 22, 777-783.	1.0	13
95	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2 infected patients in a real-world setting in Japan. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1266-1275.	1.0	13
96	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1229-1237.	1.4	13
97	Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
98	Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 334-342.	1.7	13
99	Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. <i>Journal of Medical Virology</i> , 2019, 91, 1837-1844.	2.5	12
100	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	4.2	12
101	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. <i>ESMO Open</i> , 2021, 6, 100190.	2.0	12
102	Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios. <i>Nutrition and Cancer</i> , 2019, 71, 1132-1141.	0.9	11
103	Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1765-1771.	1.4	10
104	Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis. <i>Hepatology Research</i> , 2014, 44, 288-295.	1.8	10
105	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1451-1458.	0.8	10
106	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. <i>Hepatology Communications</i> , 2022, 6, 461-472.	2.0	10
107	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. <i>Hepatology Research</i> , 2019, 49, 369-376.	1.8	9
108	Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 359-370.	1.9	9

#	ARTICLE	IF	CITATIONS
109	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 261-268.	0.8	9
110	Accurate and rapid identification of feeding arteries with multidetector-row angiography-assisted computed tomography for transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2015, 50, 1190-1196.	2.3	8
111	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. <i>Liver International</i> , 2018, 38, 2260-2268.	1.9	8
112	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4939.	1.8	8
113	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2202-2209.	1.4	8
114	Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>Hepatology Research</i> , 2021, 51, 860-869.	1.8	8
115	Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy. <i>Journal of Gastroenterology</i> , 2015, 50, 795-804.	2.3	7
116	Extra-hepatic feeding arteries of hepatocellular carcinoma: An investigation based on intra-arterial CT aortography images using an angio-MDCT system. <i>European Journal of Radiology</i> , 2016, 85, 1400-1406.	1.2	7
117	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1232-1238.	1.9	7
118	Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1001-1013.	1.8	7
119	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. <i>Hepatology Research</i> , 2022, 52, 235-246.	1.8	7
120	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2019, 54, 829-836.	2.3	6
121	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 203.	1.7	6
122	Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade). <i>Journal of Gastroenterology</i> , 2022, 57, 581-586.	2.3	6
123	Early detection of hepatocellular carcinoma in patients with diabetes mellitus. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 877-881.	0.8	5
124	Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. <i>Hepatology Research</i> , 2020, 50, 936-946.	1.8	5
125	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021, 99, 518-527.	0.9	5
126	Severity of liver fibrosis using shear wave elastography is influenced by hepatic necroinflammation in chronic hepatitis patients, but not in cirrhotic patients. <i>Hepatology Research</i> , 2021, 51, 436-444.	1.8	5

#	ARTICLE	IF	CITATIONS
127	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	5
128	The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan. <i>Cancer Medicine</i> , 2023, 12, 345-357.	1.3	5
129	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2975.	1.7	5
130	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4069-4069.	0.8	5
131	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2022, 29, 919-929.	1.0	5
132	A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. <i>JGH Open</i> , 2022, 6, 20-28.	0.7	4
133	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421.	1.6	4
134	Utility of combined gray-scale and perflubutane contrast-enhanced ultrasound for diagnosing early hepatocellular carcinomas: Comparison of well differentiated and distinctly nodular types. <i>Hepatology Research</i> , 2016, 46, 1214-1225.	1.8	3
135	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 538-547.	1.0	3
136	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1452-1459.	0.8	3
137	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. <i>Oncology</i> , 2022, 100, 65-73.	0.9	3
138	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 857-864.	0.8	3
139	Liver Stiffness Measurements by 2D Shear-Wave Elastography: Effect of Steatosis on Fibrosis Evaluation. <i>American Journal of Roentgenology</i> , 2022, , .	1.0	2
140	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. <i>JGH Open</i> , 2022, 6, 462-469.	0.7	2
141	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication. <i>Hepatology Research</i> , 2022, 52, 957-967.	1.8	2
142	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy. <i>GastroHep</i> , 2021, 3, 37-49.	0.3	1
143	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1293-1303.	1.0	1
144	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma. <i>Clinical Radiology</i> , 2021, , .	0.5	1

#	ARTICLE	IF	CITATIONS
145	Reply to: "HBV markers for HCC prediction: Three heads are better than two?" Journal of Hepatology, 2017, 67, 204-205.	1.8	0
146	Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. Infectious Diseases and Therapy, 2021, 10, 269-280.	1.8	0
147	A case of diffuse liver metastasis of small cell lung cancer diagnosed using contrast-enhanced ultrasonography with high-frequency transducers. Choonpa Igaku, 2021, 48, 281-286.	0.0	0
148	Serum markers of liver fibrosis. Acta Hepatologica Japonica, 2018, 59, 377-383.	0.0	0
149	Early experience using next-generation microwave ablation therapy for liver cancer. Acta Hepatologica Japonica, 2020, 61, 728-730.	0.0	0
150	Ramucirumab for HCC patients who experienced two or more systemic therapy: A multicenter study.. Journal of Clinical Oncology, 2022, 40, 395-395.	0.8	0
151	Ultrasound diagnosis of fatty liver disease. Choonpa Igaku, 2022, , .	0.0	0
152	General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy. JGH Open, 2022, 6, 487-495.	0.7	0